Reference is made to the stock exchange announcements published by IDEX Biometrics ASA (the "Company") on 29 April 2026 regarding a successfully completed private placement of 9,696,969 new shares in the Company at a subscription price of NOK 8.25 per share (the "Private Placement") and a potential subsequent repair offering (the "Subsequent Offering") directed towards existing shareholders in the Company as of 28 April 2026 (as registered in the VPS two trading days thereafter), who (i) were not included in the pre-sounding phase of the Private Placement, (ii) were not allocated Offer Shares in the Private Placement, and (iii) are not resident in a jurisdiction where such offering would be unlawful or would (in jurisdictions other than Norway) require any prospectus, filing, registration or similar action ("Eligible Shareholders").

The Subsequent Offering was made subject to (i) completion of the Private Placement, (ii) prevailing market price of the Company's shares, (iii) relevant corporate resolutions being passed by the Company, and (iv) approval and publication of a prospectus.

The Company's shares have for an extended period traded below the subscription price in the Private Placement at significant traded volumes. Since the completion of the Private Placement, the total traded volume at prices at or below the subscription price of NOK 8.25 has been significant. Accordingly, existing shareholders who did not participate in the Private Placement have had the opportunity to acquire shares at trading prices at or below the subscription price, thereby reducing the dilutive effects of the Private Placement.

In light of the above, the board of directors deems it appropriate to cancel the Subsequent Offering. The board of directors has therefore today resolved not to proceed with the Subsequent Offering.